Literature DB >> 9099183

Duration of glutamate release after acute ischemic stroke.

A Dávalos1, J Castillo, J Serena, M Noya.   

Abstract

BACKGROUND AND
PURPOSE: High levels of glutamate in plasma and cerebrospinal fluid (CSF) have been demonstrated in patients with acute ischemic stroke. The duration of this excitatory amino acid release has not been studied, and therefore the window of opportunity of treatment with glutamate antagonists is unknown. The aim of this investigation was to study the duration of the glutamate increase in patients with stable and progressing ischemic stroke.
METHODS: Glutamate in CSF was measured by high-performance liquid chromatography in 184 patients with an acute cerebral infarction of less than 24 hours' duration and in 43 control subjects.
RESULTS: Among the 120 patients with stable ischemic stroke, median glutamate levels were significantly lower- and within the reference range of control subjects-in those patients studied 6 to 24 hours from onset of symptoms than in patients studied in the first 6 hours (3 [range, 2 to 10] versus 5 mumol/L [range, 2 to 17]; P < .0001). In 64 patients with progressing ischemic stroke, glutamate concentrations measured at any time interval during the first 24 hours from onset were significantly higher than in the stable stroke and control groups.
CONCLUSIONS: The presence of glutamate increase in the CSF cannot be documented for greater than 6 hours in stable ischemic stroke. The sustained elevation of glutamate observed in progressing stroke suggests that the window to prevent neurological deterioration may be wider.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9099183     DOI: 10.1161/01.str.28.4.708

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  47 in total

1.  A new look at glutamate and ischemia: NMDA agonist improves long-term functional outcome in a rat model of stroke.

Authors:  Jasbeer Dhawan; Helene Benveniste; Zhongchi Luo; Marta Nawrocky; S David Smith; Anat Biegon
Journal:  Future Neurol       Date:  2011-11-01

2.  An organotypic hippocampal slice culture model of excitotoxic injury induced spontaneous recurrent epileptiform discharges.

Authors:  Julie M Ziobro; Laxmikant S Deshpande; Robert J Delorenzo
Journal:  Brain Res       Date:  2010-11-25       Impact factor: 3.252

3.  Human in vitro models of ischaemic stroke: a test bed for translation.

Authors:  Ana Antonic; Emily S Sena; Geoffrey A Donnan; David W Howells
Journal:  Transl Stroke Res       Date:  2012-07-21       Impact factor: 6.829

4.  Rosiglitazone attenuates cerebral vasospasm and provides neuroprotection in an experimental rat model of subarachnoid hemorrhage.

Authors:  Bo-Feng Lin; Chan-Yang Kuo; Li-Li Wen; Chun-Mei Chen; Ya-Feng Chang; Chih-Shung Wong; Chen-Hwan Cherng; Mei-Yu Chuang; Zhi-Fu Wu
Journal:  Neurocrit Care       Date:  2014-10       Impact factor: 3.210

Review 5.  Blood biomarkers of ischemic stroke.

Authors:  Glen C Jickling; Frank R Sharp
Journal:  Neurotherapeutics       Date:  2011-07       Impact factor: 7.620

6.  GOT to rid the body of excess glutamate.

Authors:  Vivian I Teichberg
Journal:  J Cereb Blood Flow Metab       Date:  2011-03-30       Impact factor: 6.200

7.  Subunit-specific desensitization of heteromeric kainate receptors.

Authors:  David D Mott; Asheebo Rojas; Janet L Fisher; Raymond J Dingledine; Morris Benveniste
Journal:  J Physiol       Date:  2009-12-21       Impact factor: 5.182

8.  Extracellular glutamate exposure facilitates group I mGluR-mediated epileptogenesis in the hippocampus.

Authors:  Wangfa Zhao; Shih-Chieh Chuang; Steven R Young; Riccardo Bianchi; Robert K S Wong
Journal:  J Neurosci       Date:  2015-01-07       Impact factor: 6.167

Review 9.  Beyond neural cubism: promoting a multidimensional view of brain disorders by enhancing the integration of neurology and psychiatry in education.

Authors:  Joseph J Taylor; Nolan R Williams; Mark S George
Journal:  Acad Med       Date:  2015-05       Impact factor: 6.893

10.  ZK200775: a phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma.

Authors:  L Turski; A Huth; M Sheardown; F McDonald; R Neuhaus; H H Schneider; U Dirnagl; F Wiegand; P Jacobsen; E Ottow
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.